INTRODUCTION {#s1}
============

Cancer stem cells (CSCs), also called tumor-initiating cells, are a small subpopulation of multipotent cancer cells with the capacity to self-renew \[[@R1], [@R2]\]. According to the CSC hypothesis, these stem-like cells play a pivotal role in tumorigenesis, metastasis and relapse \[[@R1]--[@R4]\]. Previous work showed that only CSCs could reconstitute tumors with similar histopathological characteristics to the primary cancer, whereas non-stem cancer cells failed to effect tumor initiation \[[@R1], [@R5], [@R6]\]. Additionally, cancer stem cells were shown to be involved in the process of tumor invasion, metastasis and resistance to conventional therapy, which were underlying factors in tumor recurrence and treatment failure \[[@R7]--[@R9]\].

To the best of our knowledge, the CSC hypothesis has primarily been tested via *in vitro* assays or murine transplantation experiments \[[@R9]--[@R11]\]. Clinical evidence of tumor formation by CSCs in humans, although difficult to observe, would further validate the CSC hypothesis. Through a comprehensive meta-analysis of published CSC-related research, we evaluated whether current clinical evidence supported the CSC hypothesis.

Several molecular biomarkers have been used in clinical trials to define the existence of CSCs, including CD133, CD44 and ALDH1 \[[@R12], [@R13]\]. Based on the presence or absence of CD133, tumor cells were divided into two categories: CD133^+^ and CD133^−^. CD133^+^ tumor cells isolated from postoperative specimens exhibited stem-like properties, whereas CD133^−^ tumor cells did not \[[@R14], [@R15]\]. Furthermore, CD133 was expressed uniquely by stem-like cells within tumors, but was rapidly down-regulated in their progeny, indicating that CD133^+^ tumor cells could be regarded as CSCs \[[@R15]--[@R24]\]. As a universally recognized biomarker of CSCs, CD133 has been extensively utilized to identify and isolate CSCs in a variety of human tumors, including brain tumors, prostate tumors, pancreatic adenocarcinomas, colorectal carcinomas, hepatocellular carcinomas, melanomas, breast cancers, lung cancers, laryngeal carcinomas, and osteosarcomas \[[@R6], [@R15], [@R25]--[@R28]\].

Previous studies have attempted to evaluate the role of CD133^+^ tumor cells with respect to clinicopathological features \[[@R29]--[@R42]\]. Several studies suggested that a high number of CD133^+^ tumor cells contributed to early lymph node metastasis, advanced T stages, and poorly differentiated tumors \[[@R34]--[@R37]\]. Consistent with those findings, CD133^+^ tumor cells showed greater resistance to postoperative treatment, and increased CD133 expression was observed in residual cancer cells after adjuvant therapy (AT) \[[@R41]\]. Even with radical resection, patients expressing high levels of CD133 were found to have significantly poorer survival than those with lower expression levels \[[@R37], [@R38]\]. These results were demonstrated in a disease model of colorectal cancer (CRC), which has a high incidence of recurrence and mortality \[[@R33], [@R42]\], although results from other studies were inconclusive \[[@R39], [@R40]\]. The meta-analysis described in the current work attempts to clarify the clinical value of CD133 expression in CRC patients.

Currently, CRC is the third most common cancer in the world, accounting for 10% of the global cancer burden \[[@R43], [@R44]\]. In the developed world, the high incidence of metastasis and recurrence following resection contributes to patient death in approximately one-third of cases \[[@R45], [@R46]\]. As described above, the presence of cancer stem cells may be correlated with a higher rate of treatment failure and tumor recurrence. A timely systematic review that comprehensively analyzes clinical trials measuring CD133 expression in CRCs could delineate the clinical importance of CSCs in therapeutic resistance and tumor regrowth. This work would provide not only useful information for association.

RESULTS {#s2}
=======

Study selection and characteristics {#s2_1}
-----------------------------------

The study selection procedure is outlined in Figure [1](#F1){ref-type="fig"}. Following an extensive keyword search and analyses of article content and relevance, 28 published studies with a total of 4546 CRC cases that fulfilled all inclusion criteria were included in the present meta-analysis. All included studies were case-controlled. Based on CD133 expression level, patients from all the studies were divided into two subgroups: patients with high CD133 expression levels (levels above the cut-off value) were classified into the CD133^High^ subgroup, and patients with low CD133 levels were classified into the CD133^Low^ subgroup. Overall, 23 studies comprising 1157 CD133^High^ patients and 2344 CD133^Low^ patients were included in the analyses of overall survival (OS), while 15 studies including 533 CD133^High^ patients and 1087 CD133^Low^ patients provided relevant outcomes of disease free survival (DFS).

![Flow chart for eligible articles identified in this meta-analysis](oncotarget-07-10023-g001){#F1}

The useable data and main characteristics of each article are summarized in Table [1](#T1){ref-type="table"}. Eight studies were performed in western countries, and 20 in Asia. Eighteen articles enrolled over 100 patients while the other 10 studies had relatively smaller sample sizes. Four studies measured CD133 expression levels by PCR and 24 studies used immunohistochemistry (IHC) methods. All patients received surgical treatment. Eleven articles evaluated cancer survival and recurrence in patients treated with further postoperative adjuvant therapy including radiotherapy, chemotherapy and the combination of radiotherapy and chemotherapy (AT subgroup). Patients in another six studies received neither chemotherapy nor radiotherapy after surgery (non-AT subgroup).

###### Baseline characteristics of all the included studies

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                          Ethnicity     Year   Sample size   Age (yr)                                                                                       Location        Histology                       Research techniques   Ab used                                    Positive standard
  ------------------------------- ------------- ------ ------------- ---------------------------------------------------------------------------------------------- --------------- ------------------------------- --------------------- ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------
  **Lin \[[@R52]\]**              USA           2007   66            61.3 ± 13.5                                                                                    Colon (66)      Well (4);\                      PCR                                                              CD133 mRNA levels ≥ 4.79
                                                                                                                                                                                    Mod (55);\                                                                                       
                                                                                                                                                                                    Poor (7)                                                                                         

  **Kojima \[[@R50]\]**           Japan         2008   189           62.1 ± 9.7                                                                                     Colon (66);\    Well/mod (160); Poor (29)       IHC                   anti-CD133 Ab\                             the percentage of CD133-positive cells ≥ 10%
                                                                                                                                                                    Rectum (83)                                                           (AC133, Miltenyi Biotec,)                  

  **Choi \[[@R49]\]**             South Korea   2009   523           59.0 (17--87)                                                                                  Cecum (18);\    Well (23);\                     IHC                   Polyclonal anti-CD133 Ab\                  cytoplasmic positivity
                                                                                                                                                                    Colon (255);\   Mod (393);\                                           (Santa Cruz)                               
                                                                                                                                                                    Rectum (250)    Poor (100);\                                                                                     
                                                                                                                                                                                    Un (7)                                                                                           

  **Li \[[@R51]\]**               China         2009   104           ND                                                                                             Colon (104)     Well (5);\                      IHC                   monoclonal anti-CD133 Ab\                  the percentage of CD133-positive cells ≥ 5%
                                                                                                                                                                                    Mod (80);\                                            (Abcam)                                    
                                                                                                                                                                                    Poor (19)                                                                                        

  **Wang \[[@R54]\]**             China         2009   73            50.2 ± 14.1                                                                                    Rectum (73)     Well (5);\                      IHC                   polyclonal Ab\                             the percentage of CD133-positive cells ≥ 10%
                                                                                                                                                                                    Mod (39);\                                            (Abcam)                                    
                                                                                                                                                                                    Poor (29)                                                                                        

  **Horst \[[@R53]\]**            Germany       2009   110           ND                                                                                             ND              G2 (99);\                       IHC                   monoclonal anti-CD133 Ab\                  the percentage of CD133-positive cells ≥ 50%
                                                                                                                                                                                    G3 (11)                                               (Cell Signaling Technology)                

  **Huh \[[@R56]\]**              Korea         2010   61            64 (30--78)                                                                                    Colon (30);\    Well/mod (53);\                 PCR                                                              ND
                                                                                                                                                                    Rectum (31)     Poor (8)                                                                                         

  **Artells \[[@R55]\]**          Spain         2010   64            70 (39--88)                                                                                    Colon (64)      A (9); B (55)                   PCR                                                              ND

  **Kojima \[[@R57]\]**           Japan         2010   102           55.9 ± 11.4[\*](#tfn_001){ref-type="table-fn"} 57.8 ± 9.7[\#](#tfn_002){ref-type="table-fn"}   Rectum (102)    Well/mod (160); Poor (29)       IHC                   anti-CD133 Ab\                             the percentage of CD133-positive cells ≥ 10%
                                                                                                                                                                                                                                          (AC133; Miltenyi Biotec)                   

  **Takahashi \[[@R59]\]**        Japan         2010   151           67.1 (3--89)                                                                                   Colon (99);\    Well (59);\                     IHC                   polyclonal anti-CD133 Ab\                  the percentage of CD133-positive cells ≥ 50%
                                                                                                                                                                    Rectum (52)     Mod (92)                                              (Abcam)                                    

  **Ong \[[@R58]\]**              Singapore     2010   501           ND                                                                                             ND              ND                              IHC                                                              the percentage of CD133-positive cells ≥ 10%

  **Xi \[[@R62]\]**               China         2011   201           20--81                                                                                         ND              Well (24);\                     IHC                   polyclonal anti-CD133 Ab\                  final scores (multiplying the intensity of positivity and the extent of positivity scores) ≥ 5
                                                                                                                                                                                    Mod (110);\                                           (Abcam)                                    
                                                                                                                                                                                    Poor (67)                                                                                        

  **Nagata \[[@R61]\]**           Japan         2011   58            ND                                                                                             Rectum (58)     ND                              IHC                   polyclonal anti-CD133 Ab\                  ND
                                                                                                                                                                                                                                          (AC133; ABGENT)                            

  **García \[[@R60]\]**           Spain         2011   88            66 (34--84)                                                                                    Rectum (88)     ND                              IHC                   polyclonal anti-CD133 Ab\                  the percentage of CD133-positive cells \> 10%
                                                                                                                                                                                                                                          \[AC133, Miltenyi Biotec\]                 

  **Zhang \[[@R68]\]**            China         2012   125           61.8                                                                                           Colon (125)     Well (14);\                     IHC                   monoclonal anti-CD133 Ab\                  index sum (totaling the scores of intensity and percentages) ≥ 4
                                                                                                                                                                                    Mod (102);\                                           (Novus)                                    
                                                                                                                                                                                    Poor (9)                                                                                         

  **Li \[[@R67]\]**               China         2012   200           58.1 (18--85)                                                                                  CRC             Well (61);\                     IHC                   polyclonal anti-CD133 Ab\                  final scores (multiplying the intensity of positivity and the extent of positivity scores) ≥ 4
                                                                                                                                                                                    Mod (93);\                                            (Abcam)                                    
                                                                                                                                                                                    Poor (46)                                                                                        

  **Bonetti \[[@R63]\]**          Italy         2012   95            69.4 ± 10.5                                                                                    CRC             Well (26);\                     IHC                   polyclonal anti-CD133 Ab\                  the percentage of CD133-positive cells ≥ 50%
                                                                                                                                                                                    Mod/poor (69)                                         (Santa Cruz)                               

  **Hongo \[[@R65]\]**            Japan         2012   303           61.2 ± 10.1[\*](#tfn_001){ref-type="table-fn"}\                                                Cecum (11);\    Well (224);\                    IHC                   primary anti-CD133 Ab\                     the percentage of CD133-positive cells ≥ 5%
                                                                     63.4 ± 10.9[\#](#tfn_002){ref-type="table-fn"}                                                 Colon (234);\   Mod (69);\                                            (AC133; Miltenyi Biotec)                   
                                                                                                                                                                    Rectum (58)     Poor (7);\                                                                                       
                                                                                                                                                                                    Mucinous (3)                                                                                     

  **Jao \[[@R66]\]**              China         2012   233           57.11 ± 5.85 (≤ 64);\                                                                          Colon (157);\   Well (38); Mod/poor (195)       IHC                   monoclonal anti-CD133 Ab\                  immunoreactivity scores (the percentage of CD133-positive cells at each level multiplied by the corresponding intensity) \> 150
                                                                     83.63 ± 5.86 (≥ 64)                                                                            Rectum (76)                                                           (clone C24B9, Cell Signaling Technology)   

  **Coco \[[@R64]\]**             Italy         2012   137           66.8 (31--86)                                                                                  Colon (137)     well/mod (95);\                 IHC                   polyclonal anti-CD133 Ab\                  the percentage of CD133-positive cells ≥ 5%
                                                                                                                                                                                    Poor (42)                                             (Santa Cruz)\                              
                                                                                                                                                                                                                                          monoclonal AC133 Ab\                       
                                                                                                                                                                                                                                          (Miltenyi Biotec)                          

  **Ying \[[@R70]\]**             China         2013   176           54.9 ± 13.5                                                                                    Colon (109);\   Well/mod (138); Poor (38)       IHC                   monoclonal anti-CD133 Ab\                  Using a ROC curve analysis
                                                                                                                                                                    Rectum (67)                                                           (clone AC133, Miltenyi Biotec)             

  **Mia-Jan \[[@R69]\]**          South Korea   2013   271           63.166 (27--101)                                                                               Colon (150);\   Well (16);\                     IHC                   anti-CD133 Ab\                             the percentage of CD133-positive cells ≥ 10%
                                                                                                                                                                    Rectum (121)    Mod (225);\                                           (AC133, Miltenyi Biotec)                   
                                                                                                                                                                                    Poor (30)                                                                                        

  **Shikina \[[@R72]\]**          Japan         2014   234           ND                                                                                             Colon (88);\    Well/mod (129); Poor/muc (20)   IHC                   anti-CD133 Ab\                             the percentage of CD133-positive cells ≥ 10%
                                                                                                                                                                    Rectum (61)                                                           (clone AC133)                              

  **Antonio Oliver \[[@R71]\]**   Spain         2014   123           71.73 ± 10.57                                                                                  CRC             Well (37);\                     IHC                   anti-CD133 Ab\                             NO
                                                                                                                                                                                    Mod (59);\                                            (Miltenyi Biotec)                          
                                                                                                                                                                                    Poor (21)                                                                                        

  **Zhou \[[@R74]\]**             China         2014   60            51.6 (3268)                                                                                    CRC             Well (20);\                     IHC                   anti-CD133 Ab\                             the percentage of CD133-positive cells ≥ 20%
                                                                                                                                                                                    Mod (20);\                                            (EarthOx, LLC)                             
                                                                                                                                                                                    Poor (20)                                                                                        

  **Vaz \[[@R73]\]**              Spain         2014   100           68 (45--92)                                                                                    Colon (100)     ND                              IHC                   monoclonal anti-CD133 Ab\                  the percentage of CD133-positive cells ≥ 10%
                                                                                                                                                                                                                                          (Cell Signaling Technology)                

  **Hong \[[@R75]\]**             Korea         2015   162           61 (29--85)                                                                                    Colon (88);\    Well (19);\                     IHC                   anti-CD133 Ab\                             scores of positivite tumor cells ≥ 1
                                                                                                                                                                    Rectum (74)     Mod (123);\                                           (AC133, Miltenyi Biotec)                   
                                                                                                                                                                                    Poor (20)                                                                                        

  **Jing \[[@R40]\]**             Korea         2015   36            66 (42--91)                                                                                    Colon (21);\    Well/mod (20);\                 PCR                                                              CD133 mRNA levels 12675
                                                                                                                                                                    Rectum (15)     Poor (15)                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ND, no details; IHC, immunohistochemistry; PCR, polymerase chain reaction; CRC, colorectal cancer; ROC curve, receiver operator characteristic curve; mod, moderate;

subgroup with preoperative or postoperative therapy;

subgroup with surgery alone.

Publication bias {#s2_2}
----------------

Based on the Begg\'s funnel plots, no evident asymmetrical shapes existed in either the OS or DFS analyses (Figure [2](#F2){ref-type="fig"}). Meanwhile, Begg\'s *P* values for OS and DFS were 0.083 and 0.553, respectively. These findings showed no evidence for obvious publication bias among the included studies, indicating that publication bias was not a potential source of heterogeneity in the prognostic factors.

![Begg\'s funnel plots to explore the possibility of publication bias in the pooled analyses of CD133 expression and OS (**A**) or DFS (**B**).](oncotarget-07-10023-g002){#F2}

Quantitative data synthesis {#s2_3}
---------------------------

Using methods described previously, forest plots were performed to estimate the association between CD133 and prognostic parameters. As shown in Figure [3](#F3){ref-type="fig"}, the relative risk values for OS and DFS were 0.713 (95% CI: 0.616--0.826) and 0.707 (95% CI: 0.602--0.831), respectively. The pooled analysis showed that CD133 expression was highly correlated with lower OS and DFS rates. Based on *P* value \> 0.05 and *I*^2^ \< 50%, notable heterogeneities between these studies likely existed, and the random-effect model was used to calculate the RRs of OS and DFS.

![Forest plots of RRs for the association of CD133 expression with the (A) OS and (B) DFS](oncotarget-07-10023-g003){#F3}

Sensitivity and subgroup analyses {#s2_4}
---------------------------------

Since statistically significant heterogeneity existed between the studies, further subgroup analyses were stratified by ethnicity, research techniques and therapeutic strategies. Table [2](#T2){ref-type="table"} presents the results of subgroup analysis related to the association between CD133 expression and OS or DFS. Subgroup analyses confirmed that high CD133 levels indicated a significantly poorer prognosis as compared to low levels. Ethnicity, sample size, and research technique (IHC vs. PCR) did not significantly influence the prognosis value of CD133 ([Figures S1--S3](#SD1){ref-type="supplementary-material"}). In subgroups with or without adjunctive therapy, CD133^High^ patients had poorer clinical outcomes as compared to CD133^Low^ patients (Figure [4](#F4){ref-type="fig"}).

###### Results of subgroup analysis

  Comparison variables   OS   DFS                                                          
  ---------------------- ---- ---------------------- --------- ---- ---------------------- ---------
  Sample size                                                                              
   ≥ **100**             15   0.703 (0.586--0.842)   \< 0.01   8    0.749(0.615--0.913)    \< 0.01
   \< **100**            8    0.743 (0.606--0.911)   0.086     7    0.635(0.483--0.834)    0.077
  Ethnicity                                                                                
   Asia                  17   0.705 (0.591--0.840)   \< 0.01   9    0.740(0.586--0.933)    \< 0.01
   Western countries     6    0.741 (0.588--0.934)   0.034     6    0.669(0.572--0.782)    0.531
  Research technique                                                                       
   IHC                   21   0.716 (0.613--0.836)   \< 0.01   12   0.697(0.575--0.846)    \< 0.01
   PCR                   2    0.704 (0.537--0.923)   0.430     3    0.721(0.566--0.919)    0.550
  Therapeutic strategy                                                                     
   AT                    9    0.716 (0.554--0.926)   \< 0.01   6    0.687 (0.554--0.852)   0.047
   Non-AT                4    0.623 (0.481--0.807)   0.332     4    0.651 (0.519--0.817)   0.328
   ND                    12   0.769 (0.631--0.937)   \< 0.01   7    0.748 (0.550--1.018)   \< 0.01

![The stratified analysis evaluating the association of CD133 expression with (A) OS and (B) DFS in the subgroups with or without AT](oncotarget-07-10023-g004){#F4}

DISCUSSION {#s3}
==========

Principle findings of a CSC marker based on clinical trials {#s3_1}
-----------------------------------------------------------

In the past decade, CSCs have drawn widespread attention because of their potential roles in tumorigenesis, tumor maintenance, spread and relapse. CD133^+^ tumor cells, which can be regarded as CSCs, give rise to cells with the same phenotype as the original tumor \[[@R14], [@R15], [@R28]\]. As compared to non-CSCs within tumors, CSCs are more resistant to radiotherapy and chemotherapy, and may survive these treatments to generate new lesions \[[@R47], [@R48]\]. Therefore, specific products expressed by CSCs, like CD133, may represent useful targets for clinical evaluation of tumors.

Many groups have evaluated the association between CD133^+^ CSCs and the clinical and pathological features of CRC patients, with conflicting results \[[@R40], [@R49]--[@R75]\]. In this article, we systematically analyzed published clinical data and attempted to resolve the discrepancies among these papers in order to elucidate the potential clinical relevancy of CD133 and examine the validity of the CSC hypothesis. We found that CD133 levels could provide clinically relevant prognostic information for CRC patients and could assist in the optimization of therapeutic strategies. Additionally, the prominent impact of CD133^+^ tumor cells on tumor relapse and treatment failure rates provides further evidence in support of the CSC hypothesis.

Clinical relevancy of CSC marker CD133 {#s3_2}
--------------------------------------

Several studies reported that CD133 expression was significantly correlated with histological parameters, such as tumor budding, vascular invasion, and the presence of lymph node micrometastases. Ying *et al.* suggested that low expression of CD133 in CRC primary tumors could improve survival and reduce the probability of recurrence \[[@R70]\]. Similarly, Bonetti *et al.* showed that CD133^High^ patients had shorter DFS and cancer-specific survival than CD133^Low^ cases \[[@R63]\]. In contrast, Zhou *et al.* and Hong *et al.* found no significant difference between CD133^High^ and CD133^Low^ cases in terms of survival time in CRC patients with stage I-IV disease \[[@R74], [@R75]\]. Such contrasting results made it difficult to establish CD133 as a useful marker to adequately predict the pathological features and prognostic outcomes in clinical practice.

Based on a systematic review of previous work, we found that CD133 expression was highly correlated with poor OS and DFS, indicating that CD133^+^ CSCs likely have a close relationship with patient survival and tumor relapse. Among the included studies, six selected patients who received curative surgery rather than postoperative therapy (non-AT subgroup) \[[@R53], [@R55], [@R58], [@R63], [@R72], [@R73]\]. Eleven evaluated cancer survival and recurrence among patients, all or most of whom underwent both surgical and adjuvant therapy (AT subgroup) \[[@R50], [@R51], [@R55], [@R58], [@R59], [@R67]--[@R72]\]. Stratified analysis showed that in subgroups with or without AT, CD133^High^ patients had poorer clinical outcomes as compared to CD133^Low^ patients, indicating that the prognostic significance of CD133 expression in CRC patients was not influenced by the intervention of postoperative adjuvant therapy.

The above findings demonstrated that CD133 level could be regarded as an independent and promising predictive factor for determining prognosis and likelihood of recurrence in colorectal cancer patients. Furthermore, after postoperative therapy, CD133^High^ patients exhibited significantly poorer outcomes than CD133^Low^ patients, indicating that CD133^Low^ patients might benefit from adjuvant treatments. Thus, CD133 expression also provided a promising tool for optimizing patient-specific therapeutic strategies. CD133^High^ cancer patients required further aggressive treatments or anti-CSC targeted therapy in addition to surgery and postoperative adjuvant therapy. For CD133^Low^ patients, a more moderate treatment strategy could be employed.

Evidence in support of the CSC hypothesis {#s3_3}
-----------------------------------------

According to the CSC hypothesis, tumors are initiated and manipulated by CSCs. CSCs may resist the current therapies through a multitude of mechanisms, including the presence of activated drug-efflux transporters, increased expression of intracellular detoxification enzymes, up-regulation of anti-apoptotic proteins, and enhanced efficiency of DNA repair, as well as the influences of the tumor microenvironment \[[@R9], [@R27], [@R47], [@R76]--[@R78]\]. More than previous theories involving chromosomal abnormalities, somatic mutations and multiple mutations, which suggested tumors developed as a result of chromosomal mutations and selection of clones from groups of cells over time, the CSC hypothesis may help to clarify the physiological properties of tumors and the associated biological alterations \[[@R9]\]. CD133^High^ patients generally have more CSCs and a smaller likelihood of eradicating these CSCs through conventional therapies than CD133^Low^ patients. Successful therapy for CD133^High^ patients would more likely require a combination of surgery and other complementary treatments.

Our study found that tumor relapse was positively correlated with higher CSC levels in tumors, indicating that tumor recurrence may be at least in part a result of residual CSCs persisting after surgical treatment and adjuvant therapy. Tumor initiation may also be supported by the presence of CSCs \[[@R1], [@R2], [@R79]--[@R81]\]. The processes of both tumor initiation and relapse could then be explained by the capacity of CSCs to proliferate uncontrolled, generate differentiated cancer cells and resist unfavorable environmental agents. However, because no currently available clinical data directly demonstrates an association between tumor initiation and CSCs, our tumor recurrence results provided only indirect evidence for the hypothesis that tumors may derive from CSCs. Thus, large-scale, prospective and direct clinical evidence is still required to further verify this hypothesis.

Limitations {#s3_4}
-----------

Certain limitations influenced the interpretation of our results. First, this meta-analyses confirmed the prognostic value of CSCs in CRC, but the disease model was limited to CRC. Further studies are needed to investigate the role of CSCs in other kinds of cancer. Second, clinical parameters of tumors also include tumor differentiation status, tumor staging, resection rate, etc., but relevant data were so limited that we were unable to systematically estimate the association with CD133 expression state. Third, potential publication bias might exist, which could lead to an overestimation of the clinical value of CSCs. Additional relevant reports may have appeared while we completed this study.

CONCLUSIONS {#s4}
===========

In conclusion, this meta-analysis showed that a high level of the CSC marker CD133 was significantly correlated with poor DFS and OS in CRC patients. These results suggest that CD133^+^ CSCs might be responsible for poor prognosis and early relapses (i.e., treatment failure) in the disease model of CRC. Stratified analysis of adjuvant therapy revealed that receiving adjuvant therapy did not influence the prognoses of CRC patients with high CD133 expression, indicating that CD133^High^ patients should be given novel treatments. In the AT subgroup, CD133^Low^ patients had better clinical outcomes than CD133^High^ patients, suggesting that CD133^Low^ patients could benefit from adjuvant treatments. Expanding this disease model to other kinds of cancers followed by a systematic review of additional CSC clinical data would promote further translation of the CSC hypothesis into cancer therapy. Large-scale, prospective clinical trials with advanced methodologies are still required to verify the CSC hypothesis directly.

METHODS {#s5}
=======

Literature search strategy {#s5_1}
--------------------------

Published data was systematically sought in PubMed, Embase/Medline and Web of Science, with no language restrictions, using the search terms, \["cancer stem cell," "tumor-initiating cell" OR "neoplastic Stem Cells"\] AND \["CD133," "prominin-1" OR "AC133"\] AND \["colon cancer", "rectal cancer" OR "colorectal cancer"\]. This search was regularly updated through Aug 1, 2015. The reference lists of included studies and review articles were also searched to find additional eligible studies.

Study selection {#s5_2}
---------------

Two reviewers independently reviewed all studies and selected eligible trials. The criteria for our analysis were as follows: (1) The study must be a clinical study concerning the correlation between CSCs and clinical outcomes in patients with CRCs. (2) CRCs were diagnosed by the reference standards, histopathologic analysis. (3) CD133 expression should be evaluated in primary colorectal cancer tissue. (4) Levels of CD133 were examined using immunohistochemistry (IHC) methods, tissue microarray or PCR. (5) The data provided must be sufficient to estimate either disease free survival (DFS) or overall survival (OS). (6) All cases should have a follow-up of over 2 years. Studies that could not meet any one of the above inclusion criteria were excluded. Animal studies, review articles, letters, comments, case reports and unpublished articles were also excluded. When the authors published several studies using the same subjects, only the most recent or the publication including the largest sample size was included.

Data extraction {#s5_3}
---------------

The full manuscripts of included articles were reviewed by three reviewers independently. Data extracted included first author\'s name, country of the population studied, year of publication, sample size, patient age, patient enrollment, study design, tumor site, histological grade, research technique, antibody used, positive standard, therapeutic strategy, survival outcomes and duration of follow-up. Based on characteristics of the extracted data, prognosis parameters were clarified into two groups, one group of relevant survival outcomes (including overall survival, cancer specific survival or disease specific survival) and one group of recurrence status (including recurrence free survival or disease free survival). If some articles revealed the prognosis of CRC only by Kaplan-Meier curve, the software Engauge Digitizer 4.1 (<http://sourceforge.net/projects/digitizer/>) was utilized to extract the relevant data. In case both the results of multivariate analysis and univariate analysis were provided, the former would be used in the meta-analysis. If the above information could not be retrieved from the original study, an email for help to find the relevant data was sent to the correspond author, or else the item was treated as "Not Documented (ND)". Any disagreements were resolved by consensus discussion.

Statistical analysis {#s5_4}
--------------------

The statistical package Stata (version 12.0) was used for this meta-analysis. In the forest plots, relative risks (RR) and their 95% confidence intervals (CIs) were graphically displayed to assess the association between CSCs and clinical outcomes. The Cochran\'s Q test assessed the presence of statistical heterogeneity. *I*^2^ test estimated the magnitude of heterogeneity. If the Q test showed a *P* \< 0.05 or the *I*^2^ test exhibited \> 50%, indicating significant heterogeneity between studies, the random-effect model was conducted, or the fixed-effect model was used. We then performed stratified analyses based on ethnicity, research techniques (IHC or PCR), and adjuvant therapy (surgery alone or with adjuvant therapy or not documented). Sensitivity analysis was performed to assess the stability of results. Publication bias was examined by using the Begg rank correlation method and the Egger weighted regression method.
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